Kiyohiko Hatake

7.4k total citations
237 papers, 5.1k citations indexed

About

Kiyohiko Hatake is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Kiyohiko Hatake has authored 237 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 78 papers in Pathology and Forensic Medicine and 51 papers in Genetics. Recurrent topics in Kiyohiko Hatake's work include Lymphoma Diagnosis and Treatment (69 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Cancer Treatment and Pharmacology (21 papers). Kiyohiko Hatake is often cited by papers focused on Lymphoma Diagnosis and Treatment (69 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Cancer Treatment and Pharmacology (21 papers). Kiyohiko Hatake collaborates with scholars based in Japan, United States and United Kingdom. Kiyohiko Hatake's co-authors include Yasuhito Terui, Shunji Takahashi, Yuji Mishima, Yuko Mishima, Kengo Takeuchi, Nobuyuki Mizunuma, Masahiro Yokoyama, Yoshinori Ito, Satoshi Matsusaka and Kensei Tobinai and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Kiyohiko Hatake

233 papers receiving 5.0k citations

Peers

Countries citing papers authored by Kiyohiko Hatake

Since Specialization

Citations

This map shows the geographic impact of Kiyohiko Hatake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiyohiko Hatake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiyohiko Hatake more than expected).

Fields of papers citing papers by Kiyohiko Hatake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiyohiko Hatake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiyohiko Hatake. The network helps show where Kiyohiko Hatake may publish in the future.

Co-authorship network of co-authors of Kiyohiko Hatake

This figure shows the co-authorship network connecting the top 25 collaborators of Kiyohiko Hatake. A scholar is included among the top collaborators of Kiyohiko Hatake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiyohiko Hatake. Kiyohiko Hatake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan 2024 ·International Journal of Hematology ·(unknown), Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, (unknown), (unknown), (unknown), Kensei Tobinai	1
2	A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma 2021 ·International Journal of Hematology ·Shinsuke Iida, Kazutaka Sunami, Hironobu Minami, Kiyohiko Hatake, (unknown), (unknown), (unknown), Mikael L. Rinne, Masafumi Taniwaki	15
3	Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients 2020 ·Journal of Medical Economics ·(unknown), Ayako Shoji, Kiyohiko Hatake, Naoko Oya, Ataru Igarashi	4
4	Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study 2019 ·Cancer Science ·Shinsuke Iida, Takashi Watanabe, Morio Matsumoto, Kenshi Suzuki, Kazutaka Sunami, Tadao Ishida, Kiyoshi Ando, Takaaki Chou, Shuji Ozaki, Masafumi Taniwaki, Naokuni Uike, Hirohiko Shibayama, Kiyohiko Hatake, Koji Izutsu, Takayuki Ishikawa, (unknown), Kensei Tobinai	6
5	Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan 2019 ·Cancer Science ·Wataru Munakata, Kiyoshi Ando, Kiyohiko Hatake, Noriko Fukuhara, Tomohiro Kinoshita, Suguru Fukuhara, Yukari Shirasugi, Masahiro Yokoyama, Satoshi Ichikawa, (unknown), (unknown), (unknown), Kensei Tobinai	47
6	Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan 2017 ·International Journal of Hematology ·Kiyohiko Hatake, Michinori Ogura, Kohichi Takada, Masafumi Taniwaki, Fanghong Zhang, (unknown), Kiyoshi Ando	1
7	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma 2016 ·Clinical Cancer Research ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, (unknown), M. Luisa Paccagnella, Joseph Boni, Erik Vandendries, David MacDonald	28
8	Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer 2015 ·Surgery Today ·Kokoro Kobayashi, Yoshinori Ito, Masaaki Matsuura, Ippei Fukada, Rie Horii, Shunji Takahashi, Futoshi Akiyama, Takuji Iwase, Yasuo Hozumi, Yoshikazu Yasuda, Kiyohiko Hatake	29
9	High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism 2012 ·International Immunology ·Yuji Mishima, Yasuhito Terui, Yuko Mishima, (unknown), Satoshi Matsusaka, (unknown), Kiyotsugu Kojima, Kiyohiko Hatake	28
10	Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas 2012 ·Japanese Journal of Clinical Oncology ·Kenji Nakano, (unknown), Takeshi Yuasa, Nao Nishimura, Yuji Mishima, Sakura Sakajiri, Masayuki Yokoyama, Naoko Tsuyama, (unknown), Kiyohiko Hatake	34
11	Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy 2012 ·Leukemia & lymphoma ·Kyoko Ueda, Yasuhito Terui, Masahiro Yokoyama, Sakura Sakajiri, Noriko Nishimura, Naoko Tsuyama, Kengo Takeuchi, Kiyohiko Hatake	10
12	Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? 2011 ·Breast Cancer ·Yoshinori Ito, Takuji Iwase, Kiyohiko Hatake	7
13	Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer 2011 ·Cancer Science ·Takeshi Yuasa, Shunji Takahashi, Kiyohiko Hatake, Junji Yonese, Iwao Fukui	29
14	Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer 2011 ·Oncology Letters ·Yasutoshi Kuboki, Nobuyuki Mizunuma, Masato Ozaka, Mariko Ogura, Mitsukuni Suenaga, Eiji Shinozaki, Satoshi Matsusaka, (unknown), Masaaki Matsuura, Kiyohiko Hatake	10
15	Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. 2010 ·PubMed ·Hisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, Daisuke Ennishi, Takayuki Kobayashi, Koji Sano, Eiji Shinozaki, Masahiro Yokoyama, Yuko Mishima, Yasuhito Terui, Keisho Chìn, Nobuyuki Mizunuma, Yoshinori Ito, Seiichiro Nishimura, Kengo Takeuchi, Yuichi Ishikawa, Masahiko Oguchi, Mitsune Tanimoto, Kiyohiko Hatake	5
16	An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy 2009 ·Clinical Cancer Research ·Yuji Mishima, Natsuhiko Sugimura, (unknown), Yasuhito Terui, Kengo Takeuchi, (unknown), Daisuke Ennishi, Hiroaki Asai, Masahiro Yokoyama, Kiyotsugu Kojima, Kiyohiko Hatake	13
17	Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors 2008 ·Cancer Science ·Yuko Mishima, (unknown), Yasuhito Terui, Yuji Mishima, (unknown), (unknown), Toshihiro Takizawa, Shinya Kimura, Keiya Ozawa, Kiyohiko Hatake	53
18	Antitumor effect of IKKβ inhibitor IMD-0354 on bortezomib-resistant multiple myeloma cells 2007 ·Molecular Cancer Therapeutics ·(unknown), Yasuhito Terui, Yuji Mishima, (unknown), Kiyotsugu Kojima, Susumu Muto, (unknown), Shinya Kimura, Kiyohiko Hatake	1
19	5. Tanstuzumab Treatment for Breast Cancer 2007 ·Internal Medicine ·Kiyohiko Hatake, Nahomi Tokudome, Yoshinori Ito	3
20	β2-Microglobulin Identified as an Apoptosis-Inducing Factor and Its Characterization 1999 ·Blood ·Masaki Mori, Yasuhito Terui, Masayuki Ikeda, Hiroshi Tomizuka, (unknown), Tadashi Kasahara, (unknown), (unknown), Yuji Mishima, (unknown), Muneo Yamada, Seiichi Shimamura, Jiro Kikuchi, Yusuke Furukawa, Yukihito Ishizaka, Kazuma Ikeda, Hiroyuki Mano, Keiya Ozawa, Kiyohiko Hatake	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact